The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is offering $1.5 million in grants to develop and implement innovative technologies for vaccine and biological manufacturing. A major area of interest is development of alternative in vitro assays to reduce the reliance on animal testing required for lot release.

Those interested in applying for these grants must submit a four-page concept paper by September 10. This paper should present an overview of the proposed project; no teaming, detailed budget, or cost share information is required. Following submission of concept papers, invitations will be issued to participate in the Project Call 3.1 Summit in October. At this event, proposers will have opportunities to network and discuss their project. This phase will conclude with invitations issued to submit a full proposal in Stage 2 of the process.

More information about the funding opportunity, including slides from a July 23 webinar, is available at https://niimbl.force.com/s/project-call-3-1?mc_cid=6830465cd0&mc_eid=56f3c73f36. This funding opportunity is supported by the NIIMBL Global Health Fund, a collaboration between NIIMBL and the Bill & Melinda Gates Foundation.